232 related articles for article (PubMed ID: 27098427)
1. Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Du Four S; Maenhout SK; Benteyn D; De Keersmaecker B; Duerinck J; Thielemans K; Neyns B; Aerts JL
Cancer Immunol Immunother; 2016 Jun; 65(6):727-40. PubMed ID: 27098427
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B
J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577
[TBL] [Abstract][Full Text] [Related]
3. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.
Läubli H; Müller P; D'Amico L; Buchi M; Kashyap AS; Zippelius A
Cancer Immunol Immunother; 2018 May; 67(5):815-824. PubMed ID: 29487979
[TBL] [Abstract][Full Text] [Related]
4. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
[No Abstract] [Full Text] [Related]
7. Axitinib in metastatic renal cell carcinoma.
Albiges L; Gizzi M; Carton E; Escudier B
Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
[TBL] [Abstract][Full Text] [Related]
8. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
10. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer.
Severson JJ; Serracino HS; Mateescu V; Raeburn CD; McIntyre RC; Sams SB; Haugen BR; French JD
Cancer Immunol Res; 2015 Jun; 3(6):620-30. PubMed ID: 25701326
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Bouttens F; Andre C; Verschaeve V; Van Fraeyenhove F; Chaskis C; D'Haene N; Le Mercier M; Rogiers A; Michotte A; Salmon I; Neyns B
J Neurooncol; 2018 Jan; 136(1):115-125. PubMed ID: 28988341
[TBL] [Abstract][Full Text] [Related]
12. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
Zakharia Y; Zakharia K; Rixe O
Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
[TBL] [Abstract][Full Text] [Related]
13. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
14. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
15. Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer.
Bandara NA; Bates CD; Lu Y; Hoylman EK; Low PS
Mol Cancer Ther; 2017 Mar; 16(3):461-468. PubMed ID: 27980109
[TBL] [Abstract][Full Text] [Related]
16. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
[TBL] [Abstract][Full Text] [Related]
17. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.
Stehle F; Schulz K; Fahldieck C; Kalich J; Lichtenfels R; Riemann D; Seliger B
J Biol Chem; 2013 Jun; 288(23):16334-16347. PubMed ID: 23625925
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Fruehauf J; Lutzky J; McDermott D; Brown CK; Meric JB; Rosbrook B; Shalinsky DR; Liau KF; Niethammer AG; Kim S; Rixe O
Clin Cancer Res; 2011 Dec; 17(23):7462-9. PubMed ID: 21976544
[TBL] [Abstract][Full Text] [Related]
19. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
20. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
